While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Moderna is also planning to work with U.S. regulators on the timing of its next Covid vaccine. Officials will choose the next variant to target in booster shots on May 16. Then, it will be off to ...

The side effects of this booster shot are similar to those of the Moderna booster. However, research shows that people who ...

Moderna has reported preliminary clinical ... and seems to offer improved protection. The booster shot – called mRNA-1273.211 – offered better and longer-lasting protection compared to the ...

Now, what about the second booster, which, for people who received Pfizer and Moderna, would be their fourth shot? Who's eligible? Well, right now, you're eligible for a second COVID-19 booster if ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna's mRNA-1273.214 shot.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.